StoxAnthem Biosciences vs Ipca Laboratories: share price & financials comparison
NSE: ANTHEM vs IPCALAB · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Anthem Biosciences vs Ipca Laboratories at a glance
Anthem Biosciences (ANTHEM) has a market capitalisation of ₹51,594 Cr, against ₹49,263 Cr for Ipca Laboratories (IPCALAB). Over the past year Ipca Laboratories has returned +50.5%, compared with +26.0% for Anthem Biosciences. On valuation, Ipca Laboratories trades at a lower P/E of 35.1 versus 271.9. Ipca Laboratories earns a higher return on equity (16.2% vs 5.8%). Anthem Biosciences comes out ahead on financial health and technicals. Ipca Laboratories comes out ahead on size, valuation, profitability, growth and momentum. Across the scored metrics below, Anthem Biosciences leads on 4 and Ipca Laboratories on 8. On StoxGud's 10-point checklist, Anthem Biosciences scores 6/10 and Ipca Laboratories scores 9/10.
| Metric | Anthem Biosciences | Ipca Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹51,594 Cr | ₹49,263 Cr |
| Revenue (latest FY) | ₹2,124 Cr | ₹9,646 Cr |
| Net profit (latest FY) | ₹592 Cr | ₹1,141 Cr |
| Valuation | ||
| P/E | 271.9 | 35.1 |
| P/B | 15.73 | 5.68 |
| Dividend yield | — | 0.11% |
| Profitability | ||
| Return on equity | 5.8% | 16.2% |
| Net profit margin | 9.3% | 13.4% |
| Operating margin | 41.4% | 22.5% |
| Growth | ||
| Revenue growth (YoY) | +8.0% | +13.8% |
| Net profit growth (YoY) | — | +32.8% |
| Revenue CAGR (multi-year) | — | +12.2% |
| Financial health | ||
| Debt to equity | 0.01 | 0.07 |
| Momentum | ||
| 1-month return | +3.2% | +0.2% |
| 1-year return | +26.0% | +50.5% |
| 3-year CAGR | — | +25.4% |
| 5-year CAGR | — | +12.9% |
| 10-year CAGR | — | +21.0% |
| Distance from 52W high | -4.4% | -3.4% |
| Technicals | ||
| RSI (14) | 81 | 65 |
| Price vs 200-day avg | +18.4% | +15.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Anthem Biosciences | Ipca Laboratories |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 6/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Anthem Biosciences or Ipca Laboratories?
Anthem Biosciences has a market cap of ₹51,594 Cr and Ipca Laboratories has a market cap of ₹49,263 Cr as of 06 Nov 2026.
Which has a lower P/E, Anthem Biosciences or Ipca Laboratories?
Ipca Laboratories has the lower P/E: Anthem Biosciences trades at 271.9 and Ipca Laboratories at 35.1.
Which gave better returns in the last year, Anthem Biosciences or Ipca Laboratories?
Ipca Laboratories did better: Anthem Biosciences returned +26.0% and Ipca Laboratories returned +50.5% over one year.
Is Anthem Biosciences or Ipca Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Anthem Biosciences scores 6/10 and Ipca Laboratories scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.